Clinical trials: Germ Cell Tumor
Glioma (Any Grade) in the Brain
18F-Floretyrosine Expanded Access Program
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to…
- Trial name
- NCT06743100
- Testing
- 18F-Floretyrosine
- Where
- 10 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
Melanoma
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration.
- Trial name
- NCT06101134
- Testing
- relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab
- Where
- 31 sites in United States, Chile and 3 more
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Glioblastoma
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
This study is an open-label, first-in-human, dose-escalation study of CV09050101 mRNA vaccine (CVGBM) in patients with newly diagnosed "MGMT-unmethylated" Glioblastoma (GBM).
- Trial name
- NCT05938387
- Testing
- CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg
- Where
- 13 sites in Belgium, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- CureVac
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Melanoma
Phase II, 2nd Line Melanoma - RAND Monotherapy
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137…
- Trial name
- NCT00612664
- Testing
- Anti-CD137 (4-1BB) (BMS-663513)
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 158 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
- Trial name
- NCT00289016
- Testing
- Talimogene Laherparepvec
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- BioVex Limited
Glioblastoma
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery.
- Trial name
- NCT05376800
- Testing
- BI 907828 (Brigimadlin)
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Melanoma, Ovarian Cancer
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02015416
- Testing
- IDC-G305
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Metastatic Melanoma and Merkel Cell Carcinoma
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
This study will evaluate the preliminary safety, pharmacokinetics, and anti-tumor activity of pasireotide s.c. in patients with metastatic melanoma or metastatic Merkel cell carcinoma.
- Trial name
- NCT01652547
- Testing
- Pasireotide sub-cutaneous formulation, Pasireotide lon acting release formulation
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Melanoma
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy.
- Trial name
- NCT00179608
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Glioblastoma
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
This is a multicenter, open-label, randomized Phase II clinical study designed to evaluate the efficacy and safety of a personalized dendritic cell (DC) vaccine, ZSNeo-DC1.1, in combination with temozolomide (TMZ) as adjuvant…
- Trial name
- NCT07365280
- Testing
- Personalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ)
- Volunteers
- 78 people
- Sponsor
- ZSky Biotech Inc
Cancer of Colon, Malignant Melanoma
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.
- Conditions
- Cancer of Colon, Malignant Melanoma, Urologic Cancer
- Trial name
- NCT00294476
- Testing
- IVIG, Biological Therapy
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- GammaCan
Melanoma Stage IIIB, Melanoma Stage IIIC
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma…
- Conditions
- Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
- Trial name
- NeoDREAM (NCT03567889)
- Testing
- Daromun, Surgery, Adjuvant therapy
- Where
- 37 sites in United States, Spain and 1 more
- Volunteers
- 186 people
- Sponsor
- Philogen S.p.A.
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Malignant Melanoma
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage…
- Trial name
- NCT02935790
- Testing
- ACY-241, nivolumab, ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.